Short, dated updates on what actually moved in GLP-1 pricing, supply, and policy — every factual brief carries a source. We update this when the market does, not on a schedule, so a quiet week means a quiet market.
Most recent brief: AUG 6, 2026
HealthRX now lists compounded semaglutide at $133/month on a cancel-anytime plan — the lowest all-in cash price on our board, undercutting the $199 bundled option. The advertised $99/month still requires a 12-month prepay, so we publish the cancel-anytime figure, not the headline.
SkinnyRx offers a once-daily compounded tirzepatide tablet from $299/month — a route for injection-averse patients that skips needles. It is compounded, so not FDA-approved, and oral compounded tirzepatide is less established than injectables. We verified the starting price against the provider's own site.
Brand semaglutide and tirzepatide stay resolved on the FDA drug-shortage database. Mass compounding under the shortage exemption has wound down; compounded supply continues under ordinary pharmacy rules but with active regulatory attention — so who your provider sources from still matters.
Every price on our board traces to the provider's own public page, with the date we checked it. When a headline number can't be verified from a stable public source, we label it unverified rather than repeat it as fact. That's the line competitors' badge-heavy boards tend to skip.
Want the real all-in cost, not the headline?
Every brief traces back to our verified provider board and price tools.
